STOCK TITAN

[6-K] MingZhu Logistics Holdings Limited Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Intellia Therapeutics, Inc. (NTLA) – Form 4 insider filing

EVP & CFO Edward J. Dulac III executed an automatic, non-volitional sale of 7,462 common shares on 23 Jul 2025 at $14.02 per share. The disposition was a mandatory “sell-to-cover” to satisfy federal and state tax-withholding obligations triggered by the vesting of RSUs on 22 Jul 2025.

Post-transaction, Dulac directly owns 106,062 NTLA shares; no indirect holdings or derivative security changes were reported. No options were exercised or granted, and the filing does not disclose any additional share sales or purchases.

The event does not materially alter management’s economic exposure to the company and should be viewed as administrative rather than discretionary trading activity.

Intellia Therapeutics, Inc. (NTLA) – Comunicazione interna Form 4

Il Vice Presidente Esecutivo e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 al prezzo di 14,02 $ per azione. Questa vendita è stata una cessione obbligatoria “sell-to-cover” per soddisfare gli obblighi di ritenuta fiscale federale e statale derivanti dal consolidamento delle RSU avvenuto il 22 luglio 2025.

Dopo la transazione, Dulac possiede direttamente 106.062 azioni NTLA; non sono stati segnalati possedimenti indiretti o variazioni di strumenti derivati. Non sono state esercitate o concesse opzioni, e la comunicazione non riporta ulteriori vendite o acquisti di azioni.

L’operazione non modifica in modo significativo l’esposizione economica della direzione verso la società e va considerata un’attività amministrativa piuttosto che una decisione di trading discrezionale.

Intellia Therapeutics, Inc. (NTLA) – Presentación interna Formulario 4

El Vicepresidente Ejecutivo y CFO Edward J. Dulac III realizó una venta automática y no voluntaria de 7,462 acciones comunes el 23 de julio de 2025 a $14.02 por acción. La disposición fue una venta obligatoria “sell-to-cover” para cumplir con las obligaciones de retención fiscal federales y estatales generadas por la consolidación de las RSU el 22 de julio de 2025.

Tras la transacción, Dulac posee directamente 106,062 acciones de NTLA; no se reportaron participaciones indirectas ni cambios en valores derivados. No se ejercieron ni otorgaron opciones, y la presentación no revela ventas o compras adicionales de acciones.

El evento no altera materialmente la exposición económica de la dirección a la compañía y debe considerarse una actividad administrativa más que una operación discrecional.

Intellia Therapeutics, Inc. (NTLA) – Form 4 내부자 신고

부사장 겸 CFO인 Edward J. Dulac III는 2025년 7월 23일7,462 보통주를 주당 $14.02에 자동으로 비자발적으로 매도했습니다. 이 매도는 2025년 7월 22일 RSU가 확정되면서 발생한 연방 및 주 세금 원천징수 의무를 충족하기 위한 필수적인 “sell-to-cover” 처분이었습니다.

거래 이후 Dulac는 직접 106,062 NTLA 주식를 보유하고 있으며, 간접 보유나 파생상품 변동은 보고되지 않았습니다. 옵션 행사나 부여는 없었으며, 추가 주식 매매 내역도 공개되지 않았습니다.

이번 거래는 경영진의 회사에 대한 경제적 노출에 실질적인 변화를 주지 않으며, 재량적 거래 활동보다는 행정적 조치로 간주되어야 합니다.

Intellia Therapeutics, Inc. (NTLA) – Déclaration d’initié Formulaire 4

Le Vice-Président Exécutif et CFO Edward J. Dulac III a effectué une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession était une opération obligatoire de type « sell-to-cover » pour satisfaire aux obligations de retenue d’impôt fédérales et étatiques déclenchées par l’acquisition des RSU le 22 juillet 2025.

Après la transaction, Dulac détient directement 106 062 actions NTLA ; aucune détention indirecte ni modification de titres dérivés n’a été déclarée. Aucune option n’a été exercée ou accordée, et la déclaration ne révèle aucune autre vente ou achat d’actions.

Cette opération ne modifie pas de façon significative l’exposition économique de la direction à la société et doit être considérée comme une activité administrative plutôt que comme une opération discrétionnaire.

Intellia Therapeutics, Inc. (NTLA) – Insider-Meldung Form 4

EVP & CFO Edward J. Dulac III führte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zu je 14,02 $ durch. Die Veräußerung war ein verpflichtender „Sell-to-Cover“, um bundesstaatliche und staatliche Steuerabzugsverpflichtungen zu erfüllen, die durch die Vesting der RSUs am 22. Juli 2025 ausgelöst wurden.

Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; indirekte Beteiligungen oder Änderungen bei Derivaten wurden nicht gemeldet. Es wurden keine Optionen ausgeübt oder gewährt, und die Meldung enthält keine weiteren Aktienverkäufe oder -käufe.

Das Ereignis verändert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative und nicht als diskretionäre Handelsaktivität betrachtet werden.

Positive
  • Executive retains 106,062 shares, indicating continued alignment with shareholder interests.
  • Transaction was pre-programmed and tax-driven, reducing concerns about opportunistic insider selling.
Negative
  • Even administrative insider sales can create superficial bearish headlines that may pressure short-term sentiment.

Insights

TL;DR: Routine sell-to-cover, neutral signal.

The CFO’s 7,462-share sale—only ~7% of his 106k-share stake—was required to cover taxes on vested RSUs, a common practice that avoids out-of-pocket tax payments. Because the shares were disposed automatically and promptly disclosed, the transaction offers little insight into management’s outlook on NTLA fundamentals. Insider ownership remains significant, supporting alignment with shareholders. I regard the filing as operationally neutral with no valuation impact.

TL;DR: Compliant disclosure, immaterial governance impact.

The form demonstrates timely Section 16 compliance, detailing a tax-driven sale under Rule 10b5-1-like mechanics. Such sell-to-cover transactions are typically pre-approved and avoid potential trading-window issues. Retention of over 100k shares preserves meaningful ‘skin in the game,’ and no red flags emerge regarding unusual trading patterns. Governance impact is minimal; investors should focus on broader performance catalysts rather than this single administrative filing.

Intellia Therapeutics, Inc. (NTLA) – Comunicazione interna Form 4

Il Vice Presidente Esecutivo e CFO Edward J. Dulac III ha effettuato una vendita automatica e non volontaria di 7.462 azioni ordinarie il 23 luglio 2025 al prezzo di 14,02 $ per azione. Questa vendita è stata una cessione obbligatoria “sell-to-cover” per soddisfare gli obblighi di ritenuta fiscale federale e statale derivanti dal consolidamento delle RSU avvenuto il 22 luglio 2025.

Dopo la transazione, Dulac possiede direttamente 106.062 azioni NTLA; non sono stati segnalati possedimenti indiretti o variazioni di strumenti derivati. Non sono state esercitate o concesse opzioni, e la comunicazione non riporta ulteriori vendite o acquisti di azioni.

L’operazione non modifica in modo significativo l’esposizione economica della direzione verso la società e va considerata un’attività amministrativa piuttosto che una decisione di trading discrezionale.

Intellia Therapeutics, Inc. (NTLA) – Presentación interna Formulario 4

El Vicepresidente Ejecutivo y CFO Edward J. Dulac III realizó una venta automática y no voluntaria de 7,462 acciones comunes el 23 de julio de 2025 a $14.02 por acción. La disposición fue una venta obligatoria “sell-to-cover” para cumplir con las obligaciones de retención fiscal federales y estatales generadas por la consolidación de las RSU el 22 de julio de 2025.

Tras la transacción, Dulac posee directamente 106,062 acciones de NTLA; no se reportaron participaciones indirectas ni cambios en valores derivados. No se ejercieron ni otorgaron opciones, y la presentación no revela ventas o compras adicionales de acciones.

El evento no altera materialmente la exposición económica de la dirección a la compañía y debe considerarse una actividad administrativa más que una operación discrecional.

Intellia Therapeutics, Inc. (NTLA) – Form 4 내부자 신고

부사장 겸 CFO인 Edward J. Dulac III는 2025년 7월 23일7,462 보통주를 주당 $14.02에 자동으로 비자발적으로 매도했습니다. 이 매도는 2025년 7월 22일 RSU가 확정되면서 발생한 연방 및 주 세금 원천징수 의무를 충족하기 위한 필수적인 “sell-to-cover” 처분이었습니다.

거래 이후 Dulac는 직접 106,062 NTLA 주식를 보유하고 있으며, 간접 보유나 파생상품 변동은 보고되지 않았습니다. 옵션 행사나 부여는 없었으며, 추가 주식 매매 내역도 공개되지 않았습니다.

이번 거래는 경영진의 회사에 대한 경제적 노출에 실질적인 변화를 주지 않으며, 재량적 거래 활동보다는 행정적 조치로 간주되어야 합니다.

Intellia Therapeutics, Inc. (NTLA) – Déclaration d’initié Formulaire 4

Le Vice-Président Exécutif et CFO Edward J. Dulac III a effectué une vente automatique et non volontaire de 7 462 actions ordinaires le 23 juillet 2025 au prix de 14,02 $ par action. Cette cession était une opération obligatoire de type « sell-to-cover » pour satisfaire aux obligations de retenue d’impôt fédérales et étatiques déclenchées par l’acquisition des RSU le 22 juillet 2025.

Après la transaction, Dulac détient directement 106 062 actions NTLA ; aucune détention indirecte ni modification de titres dérivés n’a été déclarée. Aucune option n’a été exercée ou accordée, et la déclaration ne révèle aucune autre vente ou achat d’actions.

Cette opération ne modifie pas de façon significative l’exposition économique de la direction à la société et doit être considérée comme une activité administrative plutôt que comme une opération discrétionnaire.

Intellia Therapeutics, Inc. (NTLA) – Insider-Meldung Form 4

EVP & CFO Edward J. Dulac III führte am 23. Juli 2025 einen automatischen, nicht freiwilligen Verkauf von 7.462 Stammaktien zu je 14,02 $ durch. Die Veräußerung war ein verpflichtender „Sell-to-Cover“, um bundesstaatliche und staatliche Steuerabzugsverpflichtungen zu erfüllen, die durch die Vesting der RSUs am 22. Juli 2025 ausgelöst wurden.

Nach der Transaktion besitzt Dulac direkt 106.062 NTLA-Aktien; indirekte Beteiligungen oder Änderungen bei Derivaten wurden nicht gemeldet. Es wurden keine Optionen ausgeübt oder gewährt, und die Meldung enthält keine weiteren Aktienverkäufe oder -käufe.

Das Ereignis verändert die wirtschaftliche Beteiligung des Managements am Unternehmen nicht wesentlich und sollte als administrative und nicht als diskretionäre Handelsaktivität betrachtet werden.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2025

 

Commission File Number 001-39564

 

Mingzhu Logistics Holdings Limited

(Translation of registrant’s name into English)

 

27F, Yantian Modern Industry Service Center
No. 3018 Shayan Road, Yantian District
Shenzhen, Guangdong, China 518081

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F       Form 40-F

 

 

 

 

 

Entry into a Non-binding Memorandum of Understanding

 

On July 7, 2025, Mingzhu Logistics Holdings Limited (“Mingzhu” or the “Company”) executed a non-binding memorandum of understanding (“MOU”) with ENEXTREND.VN COMPANY LIMITED (“Enextrend”), a Vietnam registered company which owns the emerging cross-border e-commerce platform – Muamau Mall. The strategic partners plan to leverage their respective expertise and resources to build a high-performance cross-border logistics and supply chain efficiency. The term of the MOU is two-years, commencing from July 7, 2025, and ending on July 6, 2027, unless terminated earlier by both parties. Continuation of the cooperation contemplated by this MOU is subject to due diligence investigations by the relevant parties, the negotiation and execution of a definitive cooperation agreement, satisfaction of the conditions negotiated therein including the approval of the Company’s board of directors. There is no assurance that a definitive agreement will be entered into or that the proposed cooperation will be consummated. The Company will provide further disclosure as required by the U.S. Securities and Exchange Commission as the project progresses.

 

Both parties plan to establish a strategic partnership based on resource sharing and complementary advantages. As a company focusing on logistics and supply chain management, MingZhu aims to achieve common development and enhance the core competitiveness of both parties. It plans to provide Enextrend with efficient and reliable logistics and supply chain services to support the rapid development of its e-commerce business and improved customer experience. The Company plans to combine the resource advantages of both parties to promote market expansion, and through the joint development of innovative logistics products and technologies, improve the intelligence level of the supply chain, and achieve product innovation and technology upgrades to meet the ever-changing market needs. The goal of the planned cooperation is to reduce operating costs, improve efficiency, enhance customer satisfaction, achieve other mutual benefits for both parties, and to jointly open up a broader market.

 

Enextrend is headquartered in Ho Chi Minh City, Vietnam. It owns and operates the Muamau Mall with a website of muamau.com. Muamau Mall is an emerging cross-border e-commerce platform that focuses mainly on fashion and sports products but also offers other categories such as daily necessities. It originated in Southeast Asia and operates in Vietnam and the United States. Muamau Mall’s core strategy is to provide competitive prices and efficient logistics to meet consumers’ demand for affordable goods and fast delivery.

 

Forward-Looking Statements

 

The statements in this report regarding the Company’s future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words “may”, “will”, “want”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “calculate” or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company’s strategic objectives, the Company’s future plans, market demand and user acceptance of the Company’s products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company’s reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China’s macroeconomic conditions, and the risks and assumptions disclosed in the Company’s reports provided to the CSRC (China Security Regulatory Commission). For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company’s relevant SEC filings for additional factors that may affect the Company’s future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MINGZHU LOGISTICS HOLDINGS LIMITED
     
Date: July 25, 2025 By: /s/ Jinlong Yang
    Name:  Jinlong Yang
    Title: Chief Executive Officer

 

2

FAQ

How many NTLA shares did the CFO sell in the July 23, 2025 Form 4?

Edward J. Dulac III sold 7,462 common shares at $14.02 each.

Was the NTLA insider sale discretionary?

No. It was a mandatory sell-to-cover transaction to pay taxes on vested RSUs.

What is the CFO’s remaining NTLA share ownership?

After the sale, he directly holds 106,062 shares.

Did the Form 4 report any option exercises or derivative activity?

No. No derivative securities were acquired or disposed of in this filing.

Does the filing indicate a change in Intellia’s executive outlook?

The filing is administrative and does not signal any shift in management sentiment.
Mingzhu Logistics Hldgs Ltd

NASDAQ:YGMZ

YGMZ Rankings

YGMZ Latest News

YGMZ Latest SEC Filings

YGMZ Stock Data

72.29M
76.00M
10.11%
0.17%
0.02%
Trucking
Industrials
Link
China
Shenzhen